50 Participants Needed

Olaparib + Durvalumab for Breast Cancer

(OlympiaN Trial)

Recruiting at 59 trial locations
AC
Overseen ByAstraZeneca Clinical Study Information Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Breakthrough TherapyThis drug has been fast-tracked for approval by the FDA given its high promise

Trial Summary

Will I have to stop taking my current medications?

The trial requires that you stop using certain medications, specifically strong or moderate CYP3A inhibitors and inducers, before starting the study. There is a washout period (time without taking certain medications) of 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents.

What data supports the effectiveness of the drug combination Olaparib and Durvalumab for breast cancer?

Research shows that the combination of Olaparib and Durvalumab, when added to standard chemotherapy, significantly increases the rate of complete cancer disappearance in patients with HER2-negative breast cancer, especially in certain high-risk groups.12345

Is the combination of Olaparib and Durvalumab safe for humans?

The combination of Olaparib and Durvalumab has been studied in various trials and is generally considered safe, with some patients experiencing side effects like immune-related reactions and fatigue. In one study, no dose-limiting toxicities were recorded, and the treatment was found to be tolerable.12367

How is the drug combination of Olaparib and Durvalumab unique for breast cancer treatment?

The combination of Olaparib and Durvalumab is unique because it combines a PARP inhibitor (Olaparib) with an immunotherapy drug (Durvalumab) to enhance antitumor activity, particularly in patients with BRCA-mutated breast cancer. This approach has shown improved response rates compared to standard chemotherapy, especially in certain high-risk subtypes of HER2-negative breast cancer.12378

What is the purpose of this trial?

This trial is testing olaparib alone and in combination with durvalumab for early-stage breast cancer patients with specific genetic markers. Olaparib stops cancer cells from repairing DNA, while durvalumab helps the immune system attack cancer. The goal is to find better treatment options for these patients.

Research Team

AF

Anitra Fielding, MBChB

Principal Investigator

AstraZeneca

Eligibility Criteria

This trial is for adults over 18 with newly diagnosed, operable breast cancer that's not spread and has specific characteristics including a BRCA1 or BRCA2 mutation. Participants must be able to use contraception, provide consent, have good organ function, weigh at least 30 kg, and have an ECOG status of 0 or 1. Exclusions include those with certain heart conditions, active hepatitis or autoimmune diseases, HIV unless well-controlled on therapy, prior breast cancer treatments or exposure to certain drugs.

Inclusion Criteria

I am fully active or restricted in physically strenuous activity but can do light work.
I am able to understand and sign the consent form.
I am using effective birth control methods.
See 6 more

Exclusion Criteria

I haven't had major surgery in the last 2 weeks.
I haven't taken immunosuppressive drugs in the last 14 days.
I am not taking any strong or moderate drugs that affect liver enzymes.
See 12 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive olaparib monotherapy or olaparib plus durvalumab combination therapy as neoadjuvant treatment

4 to 6 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

15 months

Long-term follow-up

Participants are monitored for event-free survival and adverse events

3 years

Treatment Details

Interventions

  • Durvalumab
  • Olaparib
Trial Overview The study tests Olaparib alone and in combination with Durvalumab in treating HER2 negative BRCA-mutated breast cancer. Olaparib is a PARP inhibitor approved for metastatic cases; Durvalumab is an immunotherapy approved for some lung cancers. Their combined use in breast cancer treatment remains experimental.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Cohort BExperimental Treatment1 Intervention
Cohort B will consist of a higher-risk population of participants with HER2-negative ER-negative or ER-low defined as having a tumour size of \>20 mm but ≤50 mm and N0 (T2/N0), or having a tumour size of \>1 mm but ≤20 mm and N1 (T1/N1).
Group II: Cohort AExperimental Treatment1 Intervention
Cohort A will consist of a lower-risk population of participants with HER2-negative ER-negative or ER-low defined as having a tumour size \>5 mm and ≤20 mm and N0 (T1b-c/N0).

Durvalumab is already approved in European Union, United States, Japan for the following indications:

🇪🇺
Approved in European Union as Imfinzi for:
  • Locally advanced, unresectable non-small cell lung cancer (NSCLC)
🇺🇸
Approved in United States as Imfinzi for:
  • Extensive-stage small cell lung cancer (ES-SCLC)
  • Limited-stage small cell lung cancer (LS-SCLC)
  • Locally advanced or metastatic urothelial carcinoma
🇯🇵
Approved in Japan as Imfinzi for:
  • Not specified in provided sources

Find a Clinic Near You

Who Is Running the Clinical Trial?

AstraZeneca

Lead Sponsor

Trials
4,491
Recruited
290,540,000+

Sir Pascal Soriot

AstraZeneca

Chief Executive Officer since 2012

Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris

Dr. Cristian Massacesi

AstraZeneca

Chief Medical Officer since 2021

MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology

Pascal Soriot

AstraZeneca

Chief Executive Officer since 2012

Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris

Cristian Massacesi

AstraZeneca

Chief Medical Officer since 2021

MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology

Findings from Research

Olaparib (Lynparza) is approved for treating adult patients with high-risk early breast cancer that has a germline BRCA mutation, following chemotherapy treatment.
This approval highlights Olaparib's role as an adjuvant therapy, which means it is used after initial treatments to help prevent cancer recurrence.
New Adjuvant Treatment for High-Risk Early Breast Cancer.Aschenbrenner, DS.[2022]
In a study involving 34 patients with BRCA1 or BRCA2 mutated metastatic breast cancer, the combination of olaparib and durvalumab demonstrated promising antitumor activity, with 80% of patients showing disease control at 12 weeks.
The treatment was generally safe, with 32% of patients experiencing grade 3 or worse adverse events, but no treatment-related deaths were reported, indicating a manageable safety profile for this combination therapy.
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.Domchek, SM., Postel-Vinay, S., Im, SA., et al.[2021]
The combination of durvalumab (a PD-L1 inhibitor) and olaparib (a PARP inhibitor) with standard paclitaxel chemotherapy significantly increased pathologic complete response (pCR) rates in stage II/III HER2-negative breast cancer, with rates rising from 20% to 37% overall.
While DOP showed enhanced efficacy, particularly in high-risk hormone receptor-positive/HER2-negative patients (pCR 64% vs. 22%), it also resulted in a higher incidence of immune-related grade 3 adverse events (12.3% vs. 1.3% in the control group).
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.Pusztai, L., Yau, C., Wolf, DM., et al.[2023]

References

New Adjuvant Treatment for High-Risk Early Breast Cancer. [2022]
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. [2021]
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. [2023]
Safety and efficacy of durvalumab (MEDI4736) in various solid tumors. [2022]
I-SPY2 platform: New lessons from the olaparib and durvalumab combination in breast cancer treatment. [2021]
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study. [2022]
Olaparib for the treatment of breast cancer. [2019]
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes. [2020]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security